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Abstract
Early studies of the use of antibiotics in patients with cystic fibrosis suggested that they would be of benefit in preventing or
reducing infection by Pseudomonas aeruginosa. In seeking to optimize treatment, factors such as the drug used, the dose, the
regimen and the formulation must be considered. Aminoglycosides are ideal for aerosolization because they have a long post-
antibiotic effect and have an acceptable taste. Tobramycin is one of the aminoglycosides with the lowest systemic toxicity, which
enables the aerosol delivery of doses high enough to overcome the antagonistic effects of the sputum. The most dramatic benefits
from inhaled tobramycin have been shown to occur in the first 2–4 weeks of administration. Continual administration for longer
periods can result in the development of resistance and loss of the improvement in lung function. However, this resistance is
transient, and susceptibility to tobramycin returns after a short drug holiday. Optimal drug administration therefore consists of a
4-week on, 4-week off cycle. Such a cycle also helps to maintain patient compliance. Successful drug delivery also depends upon
a formulation that does not provoke bronchoconstriction, which demands a formulation that is both preservative free, and
osmotically and pH balanced. This research has enabled the development of a novel formulation of tobramycin optimized for use
as an inhalation therapy in cystic fibrosis.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
A number of antipseudomonal antibiotics have been
aerosolized to patients with cystic fibrosis (CF). These
include amikacin w1x, carbenicillin and gentamicin w2,3x,
and tobramycin w4x. Many of the trials and ad hoc
administration did not seek to define the amount of drug
which must reach the lower respiratory tract to be active
against the infecting bacteria, primarily P. aeruginosa.
Often the dose was the amount dispensed by the phar-
macy for a single parenteral administration to an average
patient: 80 mg (in 2 ml) for gentamicin and tobramycin;
100 mg for amikacin; 80 mg for colistin methansul-
phonate; and 1000 mg for carbenicillin. Convenience
appeared to be a major factor in selecting the dose, as
well as the assumption that the majority of the drug
placed in the nebulizer would be delivered to the lower
respiratory tract of the patient. Although most of these
studies showed some efficacy, there were others in which
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no effect of aerosol antibiotic administration could be
demonstrated. As a result, a review in 1985 concluded
that routine administration of aerosolized antibiotics to
patients with CF was not warranted w5x.
However, the need for an antibiotic effective in the
treatment of opportunistic pulmonary infections in CF
remained. To meet this need, it was apparent that the
administration of aerosolized antibiotics would need to
be refined, with particular emphasis on optimizing the
choice of drug, formulation and regimen.
2. What drug?
Aminoglycoside antibiotics are among those common-
ly aerosolized because they are chemically stable, have
a long post-antibiotic effect wstill able to exert a lethal
effect on the target organism after the concentration has
decreased to below the minimal inhibitory concentration
(MIC) valuex, have a low background level of resis-
tance, and have an acceptable taste. Tobramycin is one
of the aminoglycosides with the lowest systemic toxicity,
and early empiric studies revealed that aerosol admin-
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Fig. 1. The density of P. aeruginosa m and tobramycin (s,d) con-
centration in the sputum of 10 patients with CF being treated paren-
terally with ticarcillin (250 mg kg day intravenously) andy1 y1
tobramycin (240 mg m day) during hospitalization for a pulmonaryy2
exacerbation. Tobramycin was quantified by: bioassay (s), or
radioenzymatic assay (d). The number in parentheses indicates the
number of patients completing each time point in the study. Error bars
indicate the S.E. of the means. Reproduced from w7x with permission.
Fig. 2. An ex vivo system to study interaction of antibiotics with
sputum. CF sputum (1.0 g) mechanically pooled from 10 patients was
placed in a sterile dialysis sack, which was then placed in 10 ml of
nutrient broth with or without added antibiotics. Test bacteria were
inoculated into the nutrient broth after a 4-h pre-incubation of the
sputum and the culture media. Samples of the broth were removed at
the times indicated and the density of the bacteria quantified.
istration of the intravenous formulation to a variety of
patients appeared to be well tolerated. Tobramycin has
further advantages that facilitated its study: it is a single
molecule (unlike gentamicin, which is a mixture of three
isomers); it can be quantified by existing, extremely
accurate and sensitive enzymatic and radioisotopic-based
assays; and it is available as a generic product. For
these reasons, early studies of the Seattle group focused
on tobramycin w5x.
3. What dose?
Vaudaux and Waldvogel w6x showed that, due to tight
binding to macromolecules (primarily DNA), aminog-
lycosides are biologically inactive in purulent exudates.
Although they were primarily concerned with the activ-
ity in abscesses, in which the exudate is necrotic cells
and polymorphonuclear leukocytes, it is well known
that CF patients produce sputum that always has some
purulence. We assayed sputum from patients being
treated with intravenous tobramycin for a pulmonary
exacerbation and found marked discrepancies between
the total amount of drug present (at several time points
throughout the course) by an enzymatic assay and the
amount present based on biologic activity w7x (Fig. 1).
Extending these studies to an in vitro system (in
which the sputum concentration was 10% of the total
volume, Fig. 2), we were able to show that there was
no marked difference in chemical composition between
sputum collected from patients with CF and sputum
collected from patients with chronic bronchitis and
bronchiectasis, and that both blocked the cidal activity
of aminoglycosides. In both cases, the cidal activity of
the aminoglycoside was completely inhibited by the
presence of sputum, permitting bacterial growth even
when the antibiotic concentration was 10 times the MIC
(Fig. 3) w8x.
Subsequent work was able to determine that the major
inhibitory factor of aminoglycoside bioactivity was spu-
tum glycoproteins w9x, although there was some inhibi-
tion by DNA binding and by divalent cations as well as
monovalent ions.
The recognition that binding was the major factor
antagonistic against aminoglycoside activity, coupled
with the availability of an in vitro system, permitted us
to show that increasing the concentration of the amino-
glycoside would ultimately result in a ‘free fraction’
able to kill P. aeruginosa; we determined that this was
the case for both gentamicin and tobramycin w6,8x. To
define the activity that would be effective against P.
aeruginosa in sputum (and in the patient), we studied
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Fig. 3. Mean bacterial density of six P. aeruginosa isolates (tobra-
mycin MIC -4 mg ml ) over time in sputum alone (s) and withy1
the addition of tobramycin 10=MIC (m) and 25=MIC (j). Error
bars indicate the S.E. of the mean. The experimental system is that
described in Fig. 2, except the pre-incubation was 28 h. Reproduced
from w7x with permission.
Fig. 4. The change in pulmonary function wFEV (j), FVC (d), and1
RV•TLC (m)x in 22 patients with CF during daily inhalation ofy1
tobramycin (mean dose 660 mg tid) for 90 days. Dashed lines indicate
follow-up after discontinuation of administration (days 99–165). The
forced vital capacity (FVC) and forced expiratory volume at one sec-
ond (FEV ) are expressed as the mean percent change from the enroll-1
ment value in liters. The ratio of the residual volume (RV) to the
total lung capacity (TLC) is expressed as the mean percent change
from enrollment. The standard deviation for the FVC at all time points
range from 10–14% while for the FEV it was 22–25% and for the1
RVyTLC, 5–8%. w11x Copyright 1989 John Wiley & Sons. This mate-
rial is used by permission of Wiley-Liss Inc, a subsidary of John
Wiley & Sons, Inc.
multiples of the in vitro-determined minimal concentra-
tion of tobramycin which would inhibit growth. Using
this in vitro system, we found that an aminoglycoside
concentration, which was 25-fold the MIC, was neces-
sary before cidal activity against six P. aeruginosa
isolates from CF patients was observed w7x (Fig. 3).
All these experiments used P. aeruginosa that were
defined as susceptible on the basis of disk susceptibility
testing, and were later confirmed to be so with a
quantitative method (broth dilution). Thus, using stan-
dard assays, all these organisms were susceptible in
vitro to tobramycin with a MICF4 mg ml , yety1
approximately 100 mg ml was required to kill themy1
in the presence of the ‘average’ CF sputum. Examination
of a panel of sputum samples from CF patients at
multiple US centers permitted us to show that there was
marked variability in the ‘antagonistic’ activity of the
sputum against aminoglycoside killing capacity. Thus,
to overcome the inhibitory activity of sputum in 100%
of the patients (i.e. including those with the ‘worst case’
sputum), the peak sputum tobramycin concentration had
to be 100 times the MIC to ensure killing of P.
aeruginosa. In the patient, this translates into a desired
peak of 400 mg of tobramycinyg of sputum.
Preliminary studies indicated that this peak sputum
concentration was achievable with an ultrasonic nebuliz-
er and aerosolizing an average of 660 mg of tobramycin
to each patient. This produced a ‘peak’ sputum tobra-
mycin concentration 30 min after the dose of 400–
12 000 mg g , with an average concentration of 4.5y1
mg g . Studies of the elimination of tobramycin fromy1
sputum w10x had indicated that the concentration would
decrease to below the in vitro MIC at approximately 6
h. Taking into account the 2-h post-antibiotic effect seen
in vitro, it was determined that the theoretically ideal
administration frequency was every 8 h, and therefore
the dose was administered three times daily.
This dosage regimen was shown to be well tolerated
in a 90-day study of 22 patients with CF w11x. Extensive
testing of renal function indicated no nephrotoxicity, and
testing of auditory acuity to 20 000 Hz (that frequency
first affected by aminoglycosides) did not detect any
ototoxicity. Vestibular function was also unaffected when
tested with the ‘dynamic E test’.
With safety of high doses for 3 months demonstrated
a double-blind, placebo-controlled, taste-masked, cross-
over study was performed in 71 patients with CF. This
study revealed a marked decrease in sputum bacterial
density with aerosol tobramycin administration (indicat-
ing killing of P. aeruginosa), and that this decrease in
density correlated with an improvement in pulmonary
function w12x.
4. What regimen?
In the open, unblinded studies of the safety of daily
aerosol tobramycin administration, serial measurements
of pulmonary function were performed w11x. It was
noted that the most dramatic improvement in pulmonary
function occurred 2 weeks after initiation of administra-
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Fig. 5. The median, 10th and 90th percentile values of sputum tobra-
mycin concentrations (mg g ) measured at 10, 60 and 120 min fol-y1
lowing completion of aerosol administration of tobramycin via ultra
(j), sidestream (d), and parijet (m) nebulizers. With the Ultra, 600
mg of tobramycin (30 mg ml in 0.5 normal saline) was aerosolizedy1
in 12 min, while with the jet nebulizers, 300 mg of tobramycin (60
mg ml in 0.25 normal saline) was nebulized in approximately they1
same period of time. Reproduced from w14x with permission.
tion (Fig. 4). With continued administration, the
improvement in mean FEV was maintained for an1
additional 2 weeks, but there was loss of the initial
improvement in the force vital capacity. A similar trend
was reflected in air trapping (RVyTLC ratio). These
data indicated that maximum efficacy of aerosol tobra-
mycin administration continues for no longer than 30
days.
It is clear that P. aeruginosa can develop resistance
during a 2-week course of antibiotics. For example, in
a study of azlocillin and tobramycin, 6 out of 114
morphotypes (5%) isolated from 57 patients were resis-
tant to tobramycin and azlocillin on enrolment w13x. At
the end of the treatment, 17 out of 96 morphotypes
(18%) isolated from 40 patients were now resistant to
those two antibiotics. The follow-up culture, 2–8 weeks
after the end of treatment, indicated that only four out
of 48 morphotypes (8%) were resistant w13x.
Because of the transient nature of resistance and the
failure to maintain improved pulmonary function with
daily administration greater than 30 days, an ‘on-off’
regimen seemed best suited for patients with CF. To
make the aerosol treatment of lung infection in patients
with CF practical, the patients in the initial clinical trial
w12x were surveyed to determine the most practical
regimen for in-home use. This survey revealed that
many of the patients had, in fact, skipped the middle-
of-the-day dose because it interfered with school or
work.
A further trial was conducted in 67 CF patients using
a more concentrated formulation of 60 mg ml tobra-y1
mycin delivered via the PARI LC (not plus in this
study) nebulizer. This more concentrated formulation
and jet nebuliser combination produced a median peak
sputum concentration of 452 mg g and was well-y1
tolerated w14x. Although this is only 33% of the peak
concentration obtained with the larger volumes and the
ultrasonic nebulizer used in the initial study w11x, the
range of the sputum tobramycin concentrations over
time (Fig. 5) was predicted to be cidal in 90% of the
subjects. This calculation excluded those rare P. aeru-
ginosa that scored as tobramycin-susceptible on disk
testing but were in reality resistant, as well as those
uncommon patients whose sputum was exceptionally
active in blocking tobramycin activity.
5. What formulation?
Early studies aerosolizing kanamycin to CF patients
resulted in ‘bronchial irritation’ w15x. Bronchial irritation
producing cough is undesirable, because an antibiotic
which has just been deposited into the lower respiratory
tract will immediately be cleared and so will not have
time to exert its antimicrobial activity.
Other studies w16x with aerosol administration of
intravenous aminoglycosides indicated that certain for-
mulations had a bronchoconstrictor activity when admin-
istered to some CF subjects, an undesirable side-effect
in patients already suffering from obstructive lung dis-
ease. In our early studies to develop a widely usable
formulation for tobramycin aerosolization, we found that
the parenteral formulation from the pharmacy contained
preservatives that could evoke bronchospasm—not only
in the patient, but even in the medical personnel (with
asthma) conducting the study.
It is now well recognized that the preservatives in
intravenous formulations of antimicrobial agents can
evoke cough and bronchospasm when inhaled w16–19x.
To minimize bronchospasm andyor cough, the inhaled
solution must have a pH close to neutrality w20x, be
balanced for osmolarity, and it must contain an ion,
which can readily permeate the airway epithelium w21x.
Therefore, we prepared preservative-free tobramycin
at a concentration of 60 mg ml in a solution contain-y1
ing 0.25 normal saline and adjusted to pH 6.8"0.1 and
balanced for osmolality. Without antimicrobial preser-
vatives, the tobramycin formulation must be produced
under sterile conditions and dispensed in a single-use
vial. This formulation was used in the 67-patient clinical
trial of inhaled tobramycin w14x and the subsequent
large, placebo-controlled study w22x.
6. Discussion
Early studies, in which parenteral antibiotic formula-
tions were placed in nebulizers and aerosolized to
patients with CF, showed some promise in a variety of
regimens. However, concerns regarding the correct effec-
tive dose, occasional bronchospasm and cough following
aerosol administration, and the emergence of P. aerugi-
nosa resistant to the antibiotic aerosolized, curbed wide-
spread use of this form of therapy.
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In addition, concentrations far exceeding those avail-
able in parenteral formulations are necessary to achieve
an adequate concentration of unbound tobramycin in
sputum to kill P. aeruginosa after aerosol administration.
This knowledge—coupled with an understanding of the
magnitude of the sputum’s ability to block tobramycin
cidal activity, and pilot studies indicating that long-term
continuous administration becomes progressively less
beneficial—led to the development of ‘airway-friendly’
sterile formulations without preservatives and balanced
with respect to salt, pH and osmolarity. This formulation
of tobramycin (TOBI ), administered intermittently
rather than continuously, has been shown to be effective
in decreasing the sputum density of P. aeruginosa and
slowing the rate of decline in FEV .1
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